Last reviewed · How we verify
IONIS GHR-LRx
IONIS GHR-LRx is an antisense oligonucleotide that inhibits growth hormone receptor (GHR) expression to reduce growth hormone signaling.
IONIS GHR-LRx is an antisense oligonucleotide that inhibits growth hormone receptor (GHR) expression to reduce growth hormone signaling. Used for Acromegaly.
At a glance
| Generic name | IONIS GHR-LRx |
|---|---|
| Sponsor | Ionis Pharmaceuticals, Inc. |
| Drug class | Antisense oligonucleotide |
| Target | Growth hormone receptor (GHR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 2 |
Mechanism of action
The drug uses antisense technology to target and reduce messenger RNA encoding the growth hormone receptor, thereby decreasing GHR protein levels and attenuating growth hormone-mediated signaling pathways. This approach is intended to modulate pathways associated with acromegaly and other growth hormone-related disorders.
Approved indications
- Acromegaly
Common side effects
- Injection site reactions
- Liver enzyme elevation
- Platelet reduction
Key clinical trials
- A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly (PHASE2)
- Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (PHASE2)
- Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IONIS GHR-LRx CI brief — competitive landscape report
- IONIS GHR-LRx updates RSS · CI watch RSS
- Ionis Pharmaceuticals, Inc. portfolio CI